Bioprocess Automation Global Market Report 2024

The bioprocess automation market size has grown rapidly in recent years. It will grow from $5.01 billion in 2023 to $5.67 billion in 2024 at a compound annual growth rate (CAGR) of 13.2%. The expansion observed during the historical period can be attributed to several factors, including enhanced efficiency, cost reduction, risk mitigation, increasing demand for remote monitoring and control capabilities, and decreased dependency on labor.

The bioprocess automation market size is expected to see rapid growth in the next few years. It will grow to $9.1 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. Anticipated growth in the forecast period can be attributed to several factors, including enhanced productivity, regulatory compliance, process optimization, predictive maintenance, and real-time analytics. Major trends expected during this period encompass the integration of AI and machine learning technologies, the adoption of modular bioprocessing approaches, the development of process control strategies tailored for gene therapy applications, and advancements in data analytics and visualization techniques.

The surge in personalized medicine initiatives is expected to drive the expansion of the bioprocess automation market in the foreseeable future. Personalized medicine, characterized by tailoring healthcare interventions and treatments to individual patient characteristics, relies on bioprocess automation to achieve precision and scalability in producing patient-specific drugs. For instance, as reported by the Personalized Medicine Coalition, a US-based professional organization, in 2022, the approval of 12 new personalized medicines constituted approximately 34% of all newly approved therapies, marking a significant increase from previous years. Consequently, the growing adoption of personalized medicines is fueling the growth of the bioprocess automation market.

Key players in the bioprocess automation market are actively developing innovative solutions, such as bioreactors, to streamline bioprocessing operations. Bioreactors, engineered systems providing an optimal and controlled environment for biological and chemical reactions, are instrumental in simplifying the production process. For example, in April 2023, Cytiva, a US-based technology company specializing in advancing and accelerating therapeutic development and manufacturing, introduced X-platform bioreactors designed to streamline single-use upstream bioprocessing operations. These bioreactors, available in 50 and 200 L capacities, are characterized by ease of operation, flexibility, and enhanced efficiency. They contribute to increased process efficiency through ergonomic improvements, enhanced production capability, and simplified supply chain operations. Moreover, the X-platform bioreactors are versatile, catering to the manufacturing needs of cell and gene therapies, viral vectors, and monoclonal antibodies (mAbs).

In November 2021, Yokogawa Electric Corporation, a renowned Japan-based company specializing in electrical engineering and software solutions for industrial automation, test, and measurement, completed the acquisition of Insilico Biotechnology AG for an undisclosed sum. This strategic move is aimed at enhancing Yokogawa's capabilities in providing comprehensive bioprocess solutions tailored for biopharmaceutical development and manufacturing. The acquisition is particularly focused on meeting the growing demand for biopharmaceuticals with improved safety profiles. Insilico Biotechnology AG, headquartered in Germany, is recognized for its digital twin-based software and bioprocess services, which include advanced simulation of living cells and the provision of smart bioprocess development solutions to the biopharmaceutical industry.

Major companies operating in the bioprocess automation market report are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Corporation, Danaher Corporation, Amgen Inc., Merck KGaA, Parker-Hannifin Corporation, CSL Behring LLC, Rockwell Automation Inc., Agilent Technologies Inc., Lonza Group AG, Waters Corporation, Getinge AB, Eppendorf AG, Repligen Corporation, BIONET Research S.A., Flotek Industries Inc., Pierre Guerin SAS, Bioengineering AG, Genedata AG, ILS Automation, INFORS AG, Synthace Limited, Automated Control Concepts Inc., BlueSens gas sensor GmbH, DISTek Integration Inc., Securecell AG, Flownamics Analytical Instruments Inc., Inscripta Inc., PendoTECH Inc., Sartorius Stedim Biotech S.A.

North America was the largest region in the bioprocess automation market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioprocess automation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioprocess automation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bioprocess automation involves the utilization of automated systems to oversee and regulate the workflow of bioprocessing, which entails the utilization of living cells, organisms, or components to manufacture biological products such as biopharmaceuticals. Biopharmaceutical companies leverage bioprocess automation to enhance process control and optimization, improve product quality, reduce variability, increase throughput and efficiency, realize cost savings, and achieve scalability.

Key components of bioprocess automation include sensors, actuators, and controllers. Sensors function as devices that detect and respond to inputs from the physical environment, converting them into electronic signals used to monitor various parameters such as temperature, pH, dissolved oxygen, and pressure. Bioprocess automation encompasses operations across different scales, including preclinical, clinical, and commercial operations, with compatibility across batch, fed-batch, and perfusion modes of operation. Bioprocessing systems compatible with bioprocess automation include single-use systems, stainless steel, and others.

The bioprocess automation market research report is one of a series of new reports that provides bioprocess automation market statistics, including bioprocess automation industry global market size, regional shares, competitors with a bioprocess automation market share, detailed bioprocess automation market segments, market trends and opportunities, and any further data you may need to thrive in the bioprocess automation industry. This bioprocess automation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bioprocess automation market includes revenues earned by entities by providing services such as process automation, instrumentation and control systems, training and support services, and maintenance and upgrades. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioprocess automation market also includes sales of bioreactors, fermenters, laboratory information management systems (LIMS), and integrated bioprocess platforms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.